MedPlus Health Services Valuation
Is MEDPLUS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MEDPLUS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MEDPLUS (₹744.65) is trading below our estimate of fair value (₹773)
Significantly Below Fair Value: MEDPLUS is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MEDPLUS?
Key metric: As MEDPLUS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is MEDPLUS's PE Ratio? | |
|---|---|
| PE Ratio | 88.8x |
| Earnings | ₹1.00b |
| Market Cap | ₹89.02b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.6x |
| Enterprise Value/EBITDA | 36.8x |
| PEG Ratio | 2.3x |
Price to Earnings Ratio vs Peers
How does MEDPLUS's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 29.3x | ||
9627 Ain Holdings | 15.8x | 10.7% | JP¥172.6b |
002727 Yixintang Pharmaceutical Group | 52.3x | 45.8% | CN¥8.2b |
3148 Create SD Holdings | 13.4x | n/a | JP¥185.6b |
301408 Anhui Huaren Health Pharmaceutical | 35.7x | n/a | CN¥4.8b |
MEDPLUS MedPlus Health Services | 88.8x | 38.6% | ₹89.0b |
Price-To-Earnings vs Peers: MEDPLUS is expensive based on its Price-To-Earnings Ratio (88.8x) compared to the peer average (29.3x).
Price to Earnings Ratio vs Industry
How does MEDPLUS's PE Ratio compare vs other companies in the IN Consumer Retailing Industry?
Price-To-Earnings vs Industry: MEDPLUS is expensive based on its Price-To-Earnings Ratio (88.8x) compared to the Indian Consumer Retailing industry average (35x).
Price to Earnings Ratio vs Fair Ratio
What is MEDPLUS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 88.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MEDPLUS's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ₹744.65 | ₹927.00 +24.5% | 10.1% | ₹1,100.00 | ₹830.00 | n/a | 6 |
| Nov ’25 | ₹679.25 | ₹869.83 +28.1% | 8.2% | ₹1,000.00 | ₹805.00 | n/a | 6 |
| Oct ’25 | ₹664.95 | ₹869.83 +30.8% | 8.2% | ₹1,000.00 | ₹805.00 | n/a | 6 |
| Sep ’25 | ₹679.40 | ₹869.83 +28.0% | 8.2% | ₹1,000.00 | ₹805.00 | n/a | 6 |
| Aug ’25 | ₹682.10 | ₹876.00 +28.4% | 7.8% | ₹1,000.00 | ₹810.00 | n/a | 6 |
| Jul ’25 | ₹686.45 | ₹889.50 +29.6% | 8.3% | ₹1,000.00 | ₹810.00 | n/a | 6 |
| Jun ’25 | ₹731.30 | ₹874.50 +19.6% | 9.9% | ₹1,000.00 | ₹770.00 | n/a | 6 |
| May ’25 | ₹696.90 | ₹878.40 +26.0% | 13.0% | ₹1,045.00 | ₹770.00 | n/a | 5 |
| Apr ’25 | ₹698.00 | ₹878.40 +25.8% | 13.0% | ₹1,045.00 | ₹770.00 | n/a | 5 |
| Mar ’25 | ₹696.25 | ₹883.40 +26.9% | 12.7% | ₹1,045.00 | ₹770.00 | n/a | 5 |
| Feb ’25 | ₹694.50 | ₹967.80 +39.4% | 4.8% | ₹1,045.00 | ₹915.00 | n/a | 5 |
| Jan ’25 | ₹740.60 | ₹967.80 +30.7% | 4.8% | ₹1,045.00 | ₹915.00 | n/a | 5 |
| Dec ’24 | ₹792.80 | ₹963.40 +21.5% | 4.8% | ₹1,045.00 | ₹915.00 | n/a | 5 |
| Nov ’24 | ₹796.55 | ₹980.40 +23.1% | 4.4% | ₹1,045.00 | ₹930.00 | ₹679.25 | 5 |
| Oct ’24 | ₹768.85 | ₹990.40 +28.8% | 3.5% | ₹1,045.00 | ₹952.00 | ₹664.95 | 5 |
| Sep ’24 | ₹833.10 | ₹950.33 +14.1% | 10.0% | ₹1,045.00 | ₹750.00 | ₹679.40 | 6 |
| Aug ’24 | ₹949.30 | ₹893.67 -5.9% | 11.6% | ₹1,010.00 | ₹750.00 | ₹682.10 | 6 |
| Jul ’24 | ₹774.90 | ₹893.67 +15.3% | 11.6% | ₹1,010.00 | ₹750.00 | ₹686.45 | 6 |
| Jun ’24 | ₹803.85 | ₹893.67 +11.2% | 11.6% | ₹1,010.00 | ₹750.00 | ₹731.30 | 6 |
| May ’24 | ₹739.55 | ₹849.29 +14.8% | 13.3% | ₹1,100.00 | ₹750.00 | ₹696.90 | 7 |
| Apr ’24 | ₹649.70 | ₹845.00 +30.1% | 13.6% | ₹1,100.00 | ₹750.00 | ₹698.00 | 7 |
| Mar ’24 | ₹674.80 | ₹845.00 +25.2% | 13.6% | ₹1,100.00 | ₹750.00 | ₹696.25 | 7 |
| Feb ’24 | ₹637.60 | ₹854.13 +34.0% | 14.2% | ₹1,100.00 | ₹750.00 | ₹694.50 | 8 |
| Jan ’24 | ₹613.60 | ₹854.13 +39.2% | 14.2% | ₹1,100.00 | ₹750.00 | ₹740.60 | 8 |
| Dec ’23 | ₹678.40 | ₹853.29 +25.8% | 15.2% | ₹1,100.00 | ₹750.00 | ₹792.80 | 7 |
| Nov ’23 | ₹594.60 | ₹935.00 +57.2% | 14.6% | ₹1,200.00 | ₹775.00 | ₹796.55 | 8 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.